Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 12 | 2021 | 266 | 3.440 |
Why?
|
| Hyponatremia | 3 | 2023 | 10 | 2.120 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 97 | 2.090 |
Why?
|
| Child | 25 | 2023 | 1345 | 1.980 |
Why?
|
| Kidney Transplantation | 4 | 2022 | 125 | 1.640 |
Why?
|
| Kidney Failure, Chronic | 4 | 2019 | 161 | 1.610 |
Why?
|
| Sodium | 5 | 2023 | 76 | 1.580 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 49 | 1.510 |
Why?
|
| Nephrotic Syndrome | 2 | 2022 | 25 | 1.230 |
Why?
|
| Hypercalcemia | 2 | 2022 | 12 | 1.200 |
Why?
|
| Humans | 48 | 2023 | 29361 | 1.190 |
Why?
|
| Adolescent | 20 | 2021 | 2280 | 1.190 |
Why?
|
| Hydronephrosis | 2 | 2019 | 5 | 1.160 |
Why?
|
| Allopurinol | 2 | 2018 | 4 | 1.130 |
Why?
|
| Hyperkalemia | 2 | 2022 | 7 | 1.130 |
Why?
|
| Potassium | 3 | 2022 | 67 | 1.090 |
Why?
|
| Albuminuria | 4 | 2007 | 21 | 1.090 |
Why?
|
| Uric Acid | 3 | 2020 | 13 | 1.060 |
Why?
|
| Prospective Studies | 12 | 2023 | 1812 | 1.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 29 | 1.020 |
Why?
|
| Dyslipidemias | 2 | 2021 | 23 | 0.990 |
Why?
|
| Child, Preschool | 10 | 2022 | 641 | 0.980 |
Why?
|
| Antihypertensive Agents | 5 | 2019 | 85 | 0.930 |
Why?
|
| Alkalosis | 1 | 2023 | 1 | 0.920 |
Why?
|
| Alkalosis, Respiratory | 1 | 2023 | 1 | 0.920 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2007 | 24 | 0.920 |
Why?
|
| Acidosis | 1 | 2023 | 7 | 0.910 |
Why?
|
| Renin-Angiotensin System | 2 | 2021 | 7 | 0.900 |
Why?
|
| Kidney | 3 | 2022 | 173 | 0.900 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 59 | 0.890 |
Why?
|
| Cyclosporine | 1 | 2022 | 15 | 0.870 |
Why?
|
| Urine | 2 | 2019 | 9 | 0.850 |
Why?
|
| Ureteral Obstruction | 2 | 2019 | 11 | 0.830 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 1 | 0.780 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2020 | 2 | 0.780 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2020 | 2 | 0.780 |
Why?
|
| Male | 25 | 2022 | 15637 | 0.780 |
Why?
|
| Cerebrum | 1 | 2020 | 9 | 0.770 |
Why?
|
| Smoking Cessation | 1 | 2021 | 50 | 0.770 |
Why?
|
| Hyperuricemia | 2 | 2018 | 3 | 0.760 |
Why?
|
| Biomarkers | 4 | 2019 | 692 | 0.760 |
Why?
|
| Polyomavirus | 1 | 2019 | 5 | 0.730 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 9 | 0.720 |
Why?
|
| Female | 23 | 2022 | 16211 | 0.720 |
Why?
|
| Risk Factors | 10 | 2021 | 2446 | 0.690 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2019 | 1 | 0.690 |
Why?
|
| Shock | 1 | 2019 | 9 | 0.690 |
Why?
|
| Obesity | 1 | 2021 | 290 | 0.670 |
Why?
|
| Creatinine | 5 | 2021 | 44 | 0.650 |
Why?
|
| Infant | 6 | 2021 | 531 | 0.600 |
Why?
|
| C-Reactive Protein | 2 | 2007 | 125 | 0.590 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 6 | 0.560 |
Why?
|
| Hemofiltration | 1 | 2016 | 8 | 0.560 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 21 | 0.540 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 965 | 0.540 |
Why?
|
| Enalapril | 2 | 2019 | 4 | 0.530 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 9 | 0.520 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2015 | 2 | 0.520 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 4 | 0.520 |
Why?
|
| Algorithms | 3 | 2012 | 400 | 0.510 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 206 | 0.490 |
Why?
|
| Adult | 10 | 2023 | 8604 | 0.480 |
Why?
|
| Antimetabolites | 1 | 2013 | 14 | 0.480 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2019 | 2 | 0.470 |
Why?
|
| Acetazolamide | 2 | 2019 | 4 | 0.460 |
Why?
|
| Pediatrics | 1 | 2013 | 33 | 0.460 |
Why?
|
| Critical Care | 1 | 2016 | 234 | 0.460 |
Why?
|
| Physician's Role | 1 | 2013 | 17 | 0.450 |
Why?
|
| Gout | 1 | 2012 | 8 | 0.440 |
Why?
|
| Fluid Therapy | 3 | 2012 | 32 | 0.420 |
Why?
|
| Behavior Therapy | 2 | 2023 | 75 | 0.410 |
Why?
|
| HELLP Syndrome | 1 | 2010 | 2 | 0.390 |
Why?
|
| Infant, Newborn | 4 | 2019 | 604 | 0.390 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 10 | 0.390 |
Why?
|
| Placenta | 1 | 2010 | 13 | 0.390 |
Why?
|
| Disease Progression | 4 | 2019 | 788 | 0.390 |
Why?
|
| Hypophosphatemia | 1 | 2010 | 1 | 0.380 |
Why?
|
| Critical Illness | 3 | 2023 | 123 | 0.380 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 83 | 0.370 |
Why?
|
| Magnesium Deficiency | 1 | 2010 | 1 | 0.370 |
Why?
|
| Gitelman Syndrome | 1 | 2010 | 1 | 0.370 |
Why?
|
| Magnesium | 1 | 2010 | 46 | 0.360 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 23 | 0.340 |
Why?
|
| Young Adult | 3 | 2021 | 1935 | 0.330 |
Why?
|
| Cytokines | 1 | 2010 | 348 | 0.330 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2008 | 2 | 0.330 |
Why?
|
| Acid-Base Imbalance | 1 | 2008 | 2 | 0.330 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2008 | 9 | 0.330 |
Why?
|
| Hypokalemia | 1 | 2008 | 5 | 0.330 |
Why?
|
| Catecholamines | 1 | 2008 | 13 | 0.330 |
Why?
|
| Transfusion Reaction | 1 | 2008 | 9 | 0.330 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3476 | 0.320 |
Why?
|
| Blood Pressure | 5 | 2020 | 238 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 26 | 0.300 |
Why?
|
| Cerebellum | 1 | 2007 | 57 | 0.290 |
Why?
|
| Acidosis, Renal Tubular | 1 | 2006 | 2 | 0.280 |
Why?
|
| Premedication | 1 | 2006 | 4 | 0.280 |
Why?
|
| Rett Syndrome | 1 | 2006 | 6 | 0.280 |
Why?
|
| Transcription Factors | 1 | 2007 | 157 | 0.270 |
Why?
|
| Pregnancy | 2 | 2021 | 404 | 0.270 |
Why?
|
| Nail Diseases | 1 | 2005 | 1 | 0.270 |
Why?
|
| Strontium | 1 | 2005 | 2 | 0.270 |
Why?
|
| Hematuria | 1 | 2005 | 15 | 0.270 |
Why?
|
| Contrast Media | 1 | 2006 | 125 | 0.260 |
Why?
|
| Kidney Glomerulus | 1 | 2005 | 54 | 0.260 |
Why?
|
| Autonomic Dysreflexia | 1 | 2004 | 1 | 0.260 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2004 | 5 | 0.250 |
Why?
|
| Kidney Diseases | 1 | 2006 | 115 | 0.250 |
Why?
|
| Down Syndrome | 1 | 2004 | 10 | 0.250 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 129 | 0.240 |
Why?
|
| Diarrhea | 1 | 2003 | 48 | 0.230 |
Why?
|
| Hyperventilation | 1 | 2023 | 1 | 0.230 |
Why?
|
| Bicarbonates | 1 | 2023 | 3 | 0.230 |
Why?
|
| Acid-Base Equilibrium | 1 | 2023 | 5 | 0.230 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 6 | 0.230 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 11 | 0.230 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 9 | 0.220 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2023 | 148 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 36 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 33 | 0.220 |
Why?
|
| Transplant Recipients | 1 | 2022 | 23 | 0.220 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 8 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 75 | 0.220 |
Why?
|
| Steroids | 1 | 2022 | 22 | 0.220 |
Why?
|
| Rituximab | 1 | 2022 | 53 | 0.220 |
Why?
|
| ROC Curve | 2 | 2020 | 138 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2021 | 427 | 0.210 |
Why?
|
| Colistin | 1 | 2021 | 4 | 0.210 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 145 | 0.210 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 27 | 0.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 24 | 0.210 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 132 | 0.200 |
Why?
|
| Renal Dialysis | 1 | 2022 | 113 | 0.200 |
Why?
|
| Electrocardiography | 1 | 2022 | 209 | 0.200 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 150 | 0.190 |
Why?
|
| Body Size | 1 | 2020 | 11 | 0.190 |
Why?
|
| Bartter Syndrome | 1 | 2019 | 2 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2019 | 678 | 0.180 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 389 | 0.170 |
Why?
|
| Interleukin-18 | 1 | 2019 | 11 | 0.170 |
Why?
|
| Lipocalin-2 | 1 | 2019 | 2 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 100 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2019 | 66 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 521 | 0.160 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 44 | 0.160 |
Why?
|
| Age Factors | 2 | 2013 | 845 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 241 | 0.160 |
Why?
|
| Calcium | 1 | 2022 | 495 | 0.160 |
Why?
|
| Radiography | 2 | 2012 | 678 | 0.150 |
Why?
|
| Prevalence | 1 | 2019 | 491 | 0.150 |
Why?
|
| Pharmacokinetics | 1 | 2016 | 6 | 0.140 |
Why?
|
| Iran | 3 | 2020 | 36 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 24 | 0.140 |
Why?
|
| Risk | 1 | 2016 | 217 | 0.130 |
Why?
|
| Diuretics | 2 | 2019 | 15 | 0.130 |
Why?
|
| Aquaporin 2 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Cyclic GMP | 1 | 2015 | 11 | 0.130 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 30 | 0.130 |
Why?
|
| Urinalysis | 1 | 2015 | 9 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2013 | 63 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2013 | 22 | 0.110 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2012 | 1 | 0.110 |
Why?
|
| Urethral Obstruction | 1 | 2012 | 1 | 0.110 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2012 | 7 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 56 | 0.110 |
Why?
|
| Urethra | 1 | 2012 | 15 | 0.110 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2012 | 22 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2012 | 20 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2012 | 65 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2012 | 112 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 162 | 0.100 |
Why?
|
| Fetal Blood | 1 | 2010 | 16 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 55 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 2010 | 43 | 0.100 |
Why?
|
| Calcitriol | 1 | 2010 | 7 | 0.100 |
Why?
|
| Patient Selection | 1 | 2012 | 232 | 0.100 |
Why?
|
| Vitamins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Life Style | 1 | 2012 | 211 | 0.090 |
Why?
|
| Phosphates | 1 | 2010 | 21 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2010 | 108 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2012 | 140 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 223 | 0.090 |
Why?
|
| Problem Solving | 1 | 2010 | 44 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 215 | 0.090 |
Why?
|
| Furosemide | 1 | 2009 | 2 | 0.090 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 7 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 45 | 0.090 |
Why?
|
| Renin | 1 | 2008 | 2 | 0.080 |
Why?
|
| Electroretinography | 1 | 2007 | 2 | 0.080 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2007 | 2 | 0.080 |
Why?
|
| Blindness | 1 | 2007 | 14 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 161 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2007 | 298 | 0.070 |
Why?
|
| Neoplasms | 1 | 2009 | 247 | 0.070 |
Why?
|
| Water Supply | 1 | 2005 | 3 | 0.070 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2005 | 7 | 0.070 |
Why?
|
| Labetalol | 1 | 2004 | 4 | 0.060 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2004 | 4 | 0.060 |
Why?
|
| Glomerular Mesangium | 1 | 2004 | 3 | 0.060 |
Why?
|
| Drainage | 1 | 2004 | 50 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 36 | 0.060 |
Why?
|
| Dehydration | 1 | 2003 | 4 | 0.060 |
Why?
|
| Microcephaly | 1 | 2003 | 1 | 0.060 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2003 | 1 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2009 | 1939 | 0.060 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 3 | 0.060 |
Why?
|
| Ligases | 1 | 2003 | 7 | 0.060 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2003 | 3 | 0.060 |
Why?
|
| Serine | 1 | 2003 | 11 | 0.060 |
Why?
|
| Cryptorchidism | 1 | 2003 | 4 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 12 | 0.060 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2003 | 6 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 26 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2003 | 22 | 0.060 |
Why?
|
| Glycine | 1 | 2003 | 12 | 0.060 |
Why?
|
| Syndrome | 1 | 2003 | 82 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2003 | 26 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 146 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 48 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 1220 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2020 | 16 | 0.050 |
Why?
|
| Waist-Height Ratio | 1 | 2020 | 6 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2020 | 36 | 0.050 |
Why?
|
| Body Height | 1 | 2020 | 33 | 0.050 |
Why?
|
| Spironolactone | 1 | 2019 | 1 | 0.050 |
Why?
|
| Indomethacin | 1 | 2019 | 9 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 36 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3273 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 402 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 496 | 0.040 |
Why?
|